Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 + Chemo + Cetuximab/Bevacizumab in 2L MSS mCRC
NCT07253896Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate. Started Jan 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07253896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253896.